Most recently [15], we reported that SRPK2 promoted cell migration and invasion, and decreased chemosensitivity to gemcitabine or oxaliplatin treatment via the Numb and p53 signaling pathway in pancreatic cancer. Here, NUMB is linked to pancreatic neoplasm.